Literature DB >> 21076193

Methodology for determining doses to in-field, out-of-field and partially in-field organs for late effects studies in photon radiotherapy.

Rebecca M Howell1, Sarah B Scarboro, Phillip J Taddei, Sunil Krishnan, Stephen F Kry, Wayne D Newhauser.   

Abstract

An important but little examined aspect of radiation dosimetry studies involving organs outside the treatment field is how to assess dose to organs that are partially within a treatment field; this question is particularly important for studies intended to measure total absorbed dose in order to predict the risk of radiogenic late effects, such as second cancers. The purpose of this investigation was therefore to establish a method to categorize organs as in-field, out-of-field or partially in-field that would be applicable to both conventional and modern radiotherapy techniques. In this study, we defined guidelines to categorize the organs based on isodose inclusion criteria, developed methods to assess doses to partially in-field organs, and then tested the methods by applying them to a case of intensity-modulated radiotherapy for hepatocellular carcinoma based on actual patient data. For partially in-field organs, we recommend performing a sensitivity test to determine whether potential inaccuracies in low-dose regions of the DVH (from the treatment planning system) have a substantial effect on the mean organ dose, i.e. >5%. In such cases, we suggest supplementing calculated DVH data with measured dosimetric data using a volume-weighting technique to determine the mean dose.

Entities:  

Mesh:

Year:  2010        PMID: 21076193      PMCID: PMC3001332          DOI: 10.1088/0031-9155/55/23/S04

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  31 in total

1.  Experimental verification of convolution/superposition photon dose calculations for radiotherapy treatment planning.

Authors:  Maria M Aspradakis; Rachel H Morrison; Neil D Richmond; Alasdair Steele
Journal:  Phys Med Biol       Date:  2003-09-07       Impact factor: 3.609

2.  Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma.

Authors:  Phillip J Taddei; Rebecca M Howell; Sunil Krishnan; Sarah B Scarboro; Dragan Mirkovic; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2010-11-12       Impact factor: 3.609

3.  Mailable TLD system for photon and electron therapy beams.

Authors:  T H Kirby; W F Hanson; R J Gastorf; C H Chu; R J Shalek
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-02       Impact factor: 7.038

4.  Malignant neoplasms after radiation therapy for peptic ulcer.

Authors:  Zhanat A Carr; Ruth A Kleinerman; Marilyn Stovall; Robert M Weinstock; Melvin L Griem; Charles E Land
Journal:  Radiat Res       Date:  2002-06       Impact factor: 2.841

5.  Peripheral dose from megavolt beams.

Authors:  B A Fraass; J van de Geijn
Journal:  Med Phys       Date:  1983 Nov-Dec       Impact factor: 4.071

6.  Long-term risk of second malignant neoplasms after neuroblastoma in childhood: role of treatment.

Authors:  Carole Rubino; Elisabeth Adjadj; Sylvie Guérin; Catherine Guibout; Akhtar Shamsaldin; Marie-Gabrielle Dondon; Dominique Valteau-Couanet; Olivier Hartmann; Mike Hawkins; Florent de Vathaire
Journal:  Int J Cancer       Date:  2003-12-10       Impact factor: 7.396

Review 7.  Cancer risks from medical radiation.

Authors:  Elaine Ron
Journal:  Health Phys       Date:  2003-07       Impact factor: 1.316

8.  Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries.

Authors:  J D Boice; N E Day; A Andersen; L A Brinton; R Brown; N W Choi; E A Clarke; M P Coleman; R E Curtis; J T Flannery
Journal:  J Natl Cancer Inst       Date:  1985-05       Impact factor: 13.506

9.  High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group.

Authors:  Smita Bhatia; Yutaka Yasui; Leslie L Robison; Jillian M Birch; Monica K Bogue; Lisa Diller; Cyndi DeLaat; Franca Fossati-Bellani; Elaine Morgan; Odile Oberlin; Gregory Reaman; Frederick B Ruymann; Jean Tersak; Anna T Meadows
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

10.  Second primary malignancies in thyroid cancer patients.

Authors:  C Rubino; F de Vathaire; M E Dottorini; P Hall; C Schvartz; J E Couette; M G Dondon; M T Abbas; C Langlois; M Schlumberger
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

View more
  25 in total

1.  Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma.

Authors:  Phillip J Taddei; Rebecca M Howell; Sunil Krishnan; Sarah B Scarboro; Dragan Mirkovic; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2010-11-12       Impact factor: 3.609

2.  EURADOS strategic research agenda: vision for dosimetry of ionising radiation.

Authors:  W Rühm; E Fantuzzi; R Harrison; H Schuhmacher; F Vanhavere; J Alves; J F Bottollier Depois; P Fattibene; Ž Knežević; M A Lopez; S Mayer; S Miljanić; S Neumaier; P Olko; H Stadtmann; R Tanner; C Woda
Journal:  Radiat Prot Dosimetry       Date:  2015-03-09       Impact factor: 0.972

3.  Risk of radiogenic second cancers following volumetric modulated arc therapy and proton arc therapy for prostate cancer.

Authors:  Laura A Rechner; Rebecca M Howell; Rui Zhang; Carol Etzel; Andrew K Lee; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2012-10-10       Impact factor: 3.609

4.  A comparative study on the risks of radiogenic second cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation.

Authors:  Rui Zhang; Rebecca M Howell; Phillip J Taddei; Annelise Giebeler; Anita Mahajan; Wayne D Newhauser
Journal:  Radiother Oncol       Date:  2014-08-12       Impact factor: 6.280

5.  Measurement and modeling of out-of-field doses from various advanced post-mastectomy radiotherapy techniques.

Authors:  Jihyung Yoon; David Heins; Xiaodong Zhao; Mary Sanders; Rui Zhang
Journal:  Phys Med Biol       Date:  2017-11-13       Impact factor: 3.609

6.  Low- and middle-income countries can reduce risks of subsequent neoplasms by referring pediatric craniospinal cases to centralized proton treatment centers.

Authors:  Phillip J Taddei; Nabil Khater; Bassem Youssef; Rebecca M Howell; Wassim Jalbout; Rui Zhang; Fady B Geara; Annelise Giebeler; Anita Mahajan; Dragan Mirkovic; Wayne D Newhauser
Journal:  Biomed Phys Eng Express       Date:  2018-02-07

7.  Comparison of risk of radiogenic second cancer following photon and proton craniospinal irradiation for a pediatric medulloblastoma patient.

Authors:  Rui Zhang; Rebecca M Howell; Annelise Giebeler; Phillip J Taddei; Anita Mahajan; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2013-01-16       Impact factor: 3.609

8.  Impact of margin size on the predicted risk of radiogenic second cancers following proton arc therapy and volumetric modulated arc therapy for prostate cancer.

Authors:  Laura A Rechner; Rebecca M Howell; Rui Zhang; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2012-11-15       Impact factor: 3.609

9.  Comprehensive craniospinal radiation for controlling central nervous system leukemia.

Authors:  Gary V Walker; Ferial Shihadeh; Hagop Kantarjian; Pamela Allen; Gabriela Rondon; Partow Kebriaei; Susan O'Brien; Aziza Kedir; Mustefa Said; Jonathan D Grant; Deborah A Thomas; Paul W Gidley; Isidora Arzu; Chelsea Pinnix; Valerie Reed; Bouthaina S Dabaja
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-12-01       Impact factor: 7.038

10.  Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma.

Authors:  Dong Wook Kim; Kwangzoo Chung; Weon Kuu Chung; Sun Hyun Bae; Dong Oh Shin; Seongeon Hong; Sung Ho Park; Sung-Yong Park; Chae-Seon Hong; Young Kyung Lim; Dongho Shin; Se Byeong Lee; Hyun-ho Lee; Jiwon Sung; Myonggeun Yoon
Journal:  Radiat Oncol       Date:  2014-05-08       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.